Kornimate/medical-research-clean huggingface dataset:
comparison between a novel proning pillow system and standard pillows

Conditions: Pressure Ulcer

Summary: during the covid-19 pandemic, intensive care units (icus) across the country have been inundated with increasing numbers of covid patients. hypoxic patients in icu require mechanical ventilation and this can be improved by proning these patients to improve oxygenation and prevent ventilator-induced lung injury. standard practice is to use standard hospital pillows to support the pelvis and chest of the patient while they are proned. these pillows do not provide much support to the patients and often need to be adjusted due to the patient 'sinking' into them. prolonged pronation also leads to pressure sores in these anatomical locations which burden the trust financially and also cause distress to patients. a new proning pillow system was developed by dr sashika selladurai and manufactured for the icu in aintree hospital which is made from polyurethane memory foam designed to relieve pressure on the patients and prevent pressure sores that often occur during prolonged proning. the pillow system is also designed to withstand the load of heavier patients and reduce the risk of 'sinking' into the pillows when proned for long periods of time. the aim of the study is to compare the performance of the new proning pillow system with standard pillows, particularly in relation to the risk of pressure sores, by evaluating differences in chest and pelvis interface pressures between the two pillow types. this will be done by having healthy nhs staff lie on the pillows in the prone position for a short period of time while recording the pressure distribution on the pillows using pressure mats placed between them and the pillows. this will help understand the relative risk of pressure sores developing when the new pillow system is used. it is hypothesised that the new pillow system does not increase the risk of pressure sores developing. the new proning pillow system is a class 1 ce marked medical device. the proning pillow system consists of a chest pillow and a pelvis pillow made from memory foam designed to reduce contact pressures and peak interface pressures in patients and allow patients to be placed in neutral position for ventilation.


Eligibility criteria:
inclusion criteria: * work for liverpool university hospital nhs foundation trust * participant is willing and able to give informed consent for participation in the study. * agree to have weight, height, chest and waist measurements taken * agree to the study protocol * aged 18 years or above. exclusion criteria: * presentation of skin lesions * absence of any limb * female participant who is pregnant * have a lower back problem * pain or injury in shoulders or arms * history of conditions that would make it difficult to lie prone, such as pressure injury or surgery within six months leading up to the study * any conditions that significantly affect movement and sensation such as diabetes or mobility limitations
immediate detection of helicobacter infection with a new electrochemical system.

Conditions: H. Pylori Infection

Summary: helicobacter pylori-infection (h. pylori) affects about fifty percent of the general population and is associated with peptic ulcer disease, non-cardia gastric adenocarcinoma and gastric lymphoma. currently, diagnostic methods include breath tests, serology, stool antigen tests, histology or the helicobacter urease test (hut). the aim of our study is to access the clinical reliability of a new, electrochemical device for rapid h. pylori detection.

the newly developed electrochemical device for h. pylori detection consists of a working and reference electrode between which a biopsy sample is administered. afterwards, acquired voltage-values could be analysed for characteristics typical for h. pylori infection (ammonia). according to sydney classification, biopsies are taken from gastric antrum and corpus for electrochemical h. pylori detection, hut and immunohistochemistry (ihc). hut results are evaluated after 24 hours. furthermore, every patient will receive 13c-urea breath test. ihc is designated as the gold standard of h. pylori diagnosis.

Eligibility criteria:
inclusion criteria: * written informed consent * age 18-85 years * ability of subjects to understand character and individual consequences of clinical trial * subjects undergoing egd exclusion criteria: * inability to provide written informed consent * severe coagulopathy (prothrombin time \ 50 s) * pregnancy or breast feeding * active gastrointestinal bleeding * residing in institutions (e.g. prison) * ppi intake * antibiotic use, actual or within the last 4 weeks
cannabidiol in patients with heart failure failure in aha/acc stages a-c

Conditions: Heart Failure

Summary: cannabidiol in heart failure


Eligibility criteria:
inclusion criteria * men and women (women not pregnant neither in lactation period) between 30 to 75 years-old * patients with stage a-c of the american college of cardiology/american heart association classification * patients with gdmt and clinical stability within four weeks * diagnosis of ischemic or non-ischemic dilated cardiomyopathy * participants should sign an informed consent form (icf) form personally exclusion criteria * severe primary valvular cardiomyopathy or valvular prosthesis (mechanical or bio-valve) * history of heart transplant surgery, cardiomyoplasty, left ventricular reduction surgery, valvuloplasty, implantation of a ventricle assist device and surgical cardiac congenital defect correction * implantable cardioverter defibrillator within the last three months * acute coronary syndromes that required pharmacological or mechanical reperfusion or medical treatment, within 30 days before selection * percutaneous coronary intervention within 30 days prior to selection * women who are pregnant, or of childbearing potential and are not practicing an effective means of birth control * untreated thyroid disease * hepatorenal syndrome * history of seizures * hemoglobin: \< 8.5 gm/dl * wbc count lower than 3000/mm3 * platelets: \<100,000/mm * ast or alt \>2.5 × upper limit of normal (uln) unless related to primary disease * treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer) * active cancer of any etiology * history of psychiatric disorder (depression or phq-9 ≥ 10 points , bipolar syndrome, schizophrenia) or suicide attempt. * any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications * fertile female participants not applying any approved duel anti-contraceptive method * inability to comply/assist with study and follow-up procedures * patients in cardiovascular rehabilitation programs * any person who is not able to give adequate icf elimination criteria * progression of heart failure stage according to the american college of cardiology/american heart association classification, since the initiation of the study. * alt or ast \>3x normal values with a total bilirubin ≥ 2x normal value. * any degree of depression at any stage of the study

Keywords: cannabidiol heart failure aha/acc stage a-c
abdominal abscess catheter sclerotherapy (abcs)

Conditions: Abdominal Abscess

Summary: this is a single center, two arm phase i/ii clinical trial exploring the use of chemical sclerosants (ethanol and povidone iodine) in decreasing the time needed for catheter drainage for patients with non-fistulous intraabdominal abscesses. the target study sample size is 60 patients, 30 in each arm and abscess size is to be a minimum of 3cm in all 3 dimensions. the primary outcomes of interest will be tolerability and need for catheter reinsertion by one week post intervention.

this is a two-arm prospective phase i/ii clinical trial to assess the safety of a protocol of catheter-based drainage and povidone iodine or ethanol sclerotherapy of non-fistulous intraabdominal abscesses. the study aims to enroll approximately 60 total subjects with 30 per arm. the abscess should be intraperitoneal with a minimum diameter of 3cm in all three dimensions and devoid of suspicion for relation to a fistula. the described technique above will be employed to place a drainage catheter of minimum 14f in caliber and obtain an antimicrobial sample. saline lavage will be performed by irrigating the abscess and aspirating the contents until the character of the instilled and aspirated fluid are similar. following this step the cavity will be drained in full and a volume of approximately equal to the cavity of povidone iodine or ethanol will be instilled through the catheter with the catheter turned off to drainage. after approximately two minutes the drain will be opened to gravity and two minutes of additional time will be allotted to drain any excess povidone iodine or ethanol. the catheter will then be removed, and the site dressed with gauze and film dressing. the patient will then be followed clinically in the hospital for at least 48 hours and by phone check in for 7 days.

Eligibility criteria:
inclusion criteria: * male or female, aged over 18years * cross-sectional imaging (ct, us, mri) showing an intraabdominal abscess measuring at last 3cm in each dimension without fistula to the bowel or skin. * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study exclusion criteria: * pregnancy or lactation * known allergic reactions to povidone iodine or ethanol * hemodynamic instability
do prostheses of sphinkeepertm migrate after operation?

Conditions: Fecal Incontinence

Summary: 32 patients who underwent sphinkeeper operation got enrolled in this study. the primary endoint is to explore the movement of the prostheses examined by manometry and ultrasound. the secondary endpoint is to find out about the functional outcome when migration of prostheses occurs and to examine differences in morphology of the sphincters after operation.

the sphinkeepertm is a new surgical procedure in order to treat refractory fecal incontinence, which includes up to ten self-expandable prostheses. these get implanted into the intersphincteric space and due to constriction of the anal canal and better contractibility continence should be improved. because this is a new technique, there is only limited data about its clinical efficacy. in this study, patients, aged 18-90 years, who met the inclusion criteria and have received a sphinkeepertm operation, were enrolled. functional outcomes and quality of life got measured by standard questionnaires before surgery and 1, 2, 3 and 6 months after surgery. furthermore, in routine check ups patients received endoanal anorectal manometry for pressure measurement and endoanal ultrasound to determine the position of the prostheses.

Eligibility criteria:
inclusion criteria: * age 18 - 90 years, undergoing sphinkeeper operation at the department of general surgery, medical university of vienna * ability and willingness to understand and comply with study interventions and restrictions. * voluntarily signed informed consent after full explanation of the study to the participant exclusion criteria: * any physical or mental disorder, which could interfere with the participant's safety during the clinical trial or with the study objectives * inability to communicate well with the investigator due to language problems or reduced mental development * inability or unwillingness to give written informed consent
language and motricity in preterm school age children

Conditions: Infant, Premature

Summary: a total of 40% of neurodevelopmental difficulties have been reported in very premature infants less than 32 weeks of age. the epipage1 study reported a decreasing prevalence of cerebral palsy (9-6%) but a high prevalence of specific cognitive neurological difficulties and an increase in school failure. neurocognitive difficulties are numerous: visuospatial dyspraxia, language disorders, executive function disorders as well as attention and behaviour disorders. developmental language disorders have been rarely reported in the literature. this originally prompted our request i.e. phrc 2010 national multicenter: lamopresco. for the past 3 years this protocol has studied the language development of children who were born very prematurely, aged 3 and a half years free of cerebral palsy, in particular the impact of a short rehabilitation period, precise, at an early stage, and protocolized on a fundamental sensorimotor language. the principal assessment criterion was the measurement of phonology, the cornerstone of oral and written language in humans. the aim of the present project is an analysis of the effect that this specific language stimulation has on the learning of written language. the hypothesis is that a specific work modifying various aspects of a child's language, during the age of 3 to 4, alters the development of phonological skills in a sustainable way. the acquisition of reading skills is basically dependent on the quality of its phonological components. the randomized study of children up to 8 years of age in a cohort of 150 children (lamopresco) will permit to confirm or refute this hypothesis. these increasing difficulties have been reported as regards the language understanding of 3 to 15 year old children. it is as if the initial difficulties and weaknesses, which moreover constituted oral language, prevented the use or development of neural networks, which became more complex and required both an oral and written language. are these elements which constitute phonology, at an early stage, modifiable before the close of the clinically measurable developmental window?


Eligibility criteria:
inclusion criteria: * randomization in lamopresco-1 study exclusion criteria: * none as the same population as in the lamopresco study will be included

Keywords: neurological difficulties
comparing the efficacy of vhag and traditional chemotherapy regimens in newly diagnosed etp-all

Conditions: ETP-ALL

Summary: etp-all is a subtype of t-cell acute lymphoblastic leukemia (t-all) with poor outcomes and prognosis. effective induction therapy is crucial in improving the treatment effect. based on our laboratory research and clinical practice, the venetoclax plus hag regimen shows promising efficacy in treating etp-all. therefore, we plan to conduct a prospective, multicenter phase iii clinical study to evaluate the efficacy of the venetoclax plus hag regimen in treating newly diagnosed etp-all patients.


Eligibility criteria:
inclusion criteria: * age ≥14 and \<75 years old. * diagnosed with etp-all (including near-etp all) before enrollment. * newly diagnosed patients. * eastern cooperative oncology group (ecog) performance status of 0-2. * expected survival of ≥3 months. * able to undergo oral treatment with venetoclax. * no organ dysfunction that would restrict the treatment administered * understanding of the study and signing of the informed consent form. * men, women of childbearing potential (postmenopausal women must have been amenorrheic for at least 12 months to be considered infertile), and their partners must voluntarily use effective contraception methods as deemed appropriate by the investigator during the treatment period and for at least 12 months after the last dose of the study drug. exclusion criteria: * patients who are unable to take venetoclax by mouth; * patients with severe heart, lung, liver, kidney, or other organ dysfunction that may restrict their participation in this trial due to diseases; * evidence of other clinically significant uncontrolled condition(s) such as uncontrolled and/or active systemic infection (viral, bacterial or fungal) * a history of other malignant tumors within the past 5 years, excluding localized thyroid cancer and in situ skin cancer; * serum total bilirubin \>1.5 uln (upper limit of normal) (excluding leukemia infiltration); alt or ast or alp \>5 uln; serum creatinine \>1.5 uln and creatinine clearance rate \<40 ml/min; lvef \<50%; * known hiv infection; * known central nervous system leukemia infiltration; * gastrointestinal diseases known to affect venetoclax absorption as judged by the investigator; * inability to understand or comply with the study protocol.
ablation of the pulmonary artery with high pulmonary hypertension during mitral valve surgery

Conditions: Pulmonary Hypertension

Summary: the aim of this prospective randomized study was to evaluate the effectiveness and safety of the original ablation procedures ganglion plexus pulmonary artery with simultaneous correction of valvular heart disease, complicated by high pulmonary hypertension.

pulmonary hypertension is a serious condition, the severity of which is often underestimated. about 10% of significant mitral heart disease complicated by high pulmonary hypertension (more than 60 mm hg). up to 70% of patients retain this level of pulmonary hypertension after successful treatment of heart valve disease.the quality of life of patients with persistent high pulmonary hypertension is significantly lower than in patients with mild to moderate degree. risks of recurrent tricuspid insufficiency and right ventricular dysfunction is much higher. despite the use of modern drug therapy of pulmonary hypertension in patients with valvular heart disease satisfactory clinical effect is achieved only in a small number of patients. our team proposed a new original method of ablation of the pulmonary artery with simultaneous open cardiac surgery correction of mitral heart disease in patients with high baseline pulmonary hypertension.

Eligibility criteria:
inclusion criteria: * patients with mitral stenosis or insufficiency complicated by high pulmonary hypertension (mean pulmonary artery pressure in invasive monitoring more than 35 mm hg), which are subject to surgical treatment. exclusion criteria: * pulmonary stenosis; * pulmonary embolism in history; * congenital heart disease.

Keywords: pulmonary hypertension pulmonary artery denervation mitral valve disease
the treatment of purulent flexor tenosynovitis

Conditions: Tenosynovitis

Summary: this study evaluates the effect of postoperative intermittent closed-catheter irrigation on the recovery from the purulent flexor tenosynovitis. one group of patients suffering from acute purulent flexor tenosynovitis is treated using intraoperative irrigation only and the other group having both intra- and postoperative irrigation.

the foundation of the successful management of purulent flexor tenosynovitis is the surgical debridement followed by an intravenous antibiotic treatment. several surgical methods have been described to remove the purulent debris from the flexor tendon sheath. closed-catheter irrigation involves irrigation of the tendon sheath from proximal to distal direction facilitated by two small incisions; one proximal to a1 pulley and one distal to a4 pulley. lille et al. (j hand surg br. 2000;25(3):304-307) conducted a retrospective study that implied that intraoperative closed-catheter irrigation without postoperative irrigation might be as effective as the combination of intra- and postoperative irrigation. the hypothesis of this prospective randomized trial is that the intraoperative closed-catheter irrigation alone is as effective as the combination of intraoperative and postoperative intermittent closed-catheter irrigation in the treatment of purulent flexor tenosynovitis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of purulent flexor tenosynovitis with all four positive kanavel's signs: * symmetric swelling of the entire digit * exquisite tenderness along the course of the tendon sheath * semiflexed posture of the digit * pain with attempted passive extension of the digit * age over 18 years * patient's willingness to participate in the study exclusion criteria: * high-pressure, foreign body or chemical injuries, which require open debridement * prisoner, military serviceman, mental retardation or other factors which may affect one's decision making

Keywords: irrigation tenosynovitis purulent closed-catheter flexor tendon
evaluation of dentin hypersensitivity using glass ionomer cements

Conditions: Dentin Hypersensitivity

Summary: the aim of this randomized, double-blind, split-mouth clinical trial is to evaluate and compare the desensitizing efficacies of the resin-modified glass ionomer cement clinprotm xt (3m espe, minnesota, usa) and the conventional glass ionomer cement vidrion r (ss white, gloucester, uk) at 2-year follow-up.

subjects will require to have at least two teeth in different hemiarchs with dentin hypersensitivity. teeth will be randomized into 2 groups, receiving either clinpro xt or the conventional glass ionomer cement vidrion r. prior to the desensitizing treatment (baseline), painful symptoms will be assessed by tactile and air blast tests using the visual analogue scale (vas). treatment evaluations will be conducted up to 2-year post-treatment.

Eligibility criteria:
inclusion criteria: * male and female subjects between 18 and 70 years old * at least 2 teeth with dentin hypersensitivity in two different hemiarchs * dental elements with hypersensitivity without any pulp alteration * people who are not taking any medication and women who are not pregnant * patients without eating disorders or very acidic diets. exclusion criteria: * teeth with hypersensitivity that presented extensive or unsatisfactory restorations, fractures, periodontal alterations, caries lesions, orthodontic brackets, endodontic treatments, pulp alterations. * subjects who received any desensitizing therapy during the last 3 months * subjects being under analgesics/anti-inflammatory drugs at the time of the study * teeth with hypersensitivity and non-carious cervical lesions

Keywords: dentin sensitivity dentin desensitizing agents glass ionomer cements randomized controlled trial